

Hepatology

Case reports

Prof. MUDr. Libor Víték, PhD, MBA

*IV. Dept. Int Med and Institute of Clinical Biochemistry and laboratory
diagnostics*

VFN and 1. LF UK in Praze

Biochemical methods in hepatology

- ❖ **Part of a complex of laboratory methods, such as**
 - ❖ **microbiology, serology, immunology, molecular biology, function tests**
- ❖ **Static (classical LFT's) vs. Dynamic tests (breath and farmacokinetic tests)**

Biochemical exams

- ❖ Tests reflecting hepatocellular damage (ALT, AST)
- ❖ Tests reflecting damage of bile ducts and canalicular pole of hepatocytes (ALP, GGT)
- ❖ Tests measuring synthetic function of the liver (albumin, prealbumin, cholinesterase, prothrombin complex/factors)
- ❖ Tests measuring liver capacity for transport of organic anions (bilirubin, bile acids)
- ❖ Tests measuring liver capacity to metabolize endogeneous and exogeneous substances (amonia, CDT, lidocain, aminopyrine, etc.)
- ❖ Accessory tests enabling to determine right diagnosis of a disease primarily of other than liver origin (e.g. dg of metabolic syndrome in NASH/NAFLD or right heart failure)
- ❖ Specific tests for accurate diagnosis in specific liver diseases (serological tests for infectious hepatitis, specific antibodies, targeted genetic exams, metabolic diseases...)

LFT's

- ❖ **Liver function tests (LFT's) do not assess hepatic functions, they are just surrogate markers**
- ❖ **In broad context, they cover a wide range of not very specific markers**
- ❖ **Specific LFT's consists of not routinely used exams, such as breath tests (aminopyrine, galactose, chromexcretory tests...)**

LFT's

Hepatocellular damage	AST
	ALT
	LD
	GST (glutathion-S-transferáza B)
Obstruction of bile ducts	ALP
	GGT
	Conjugated bilirubin, bile acids,
Met. of organic anions	S-, U-bilirubin (direct, indirect, delta)
	U-urobilogen
	S-bile acids
Protein synthesis	albumin
	prealbumin
	Cholinesterase
	prothrombin time

LFT - use

- ❖ **Screening of liver diseases**
- ❖ **Confirmation of clinical suspicion**
- ❖ **Differential diagnosis of liver diseases**
- ❖ **Prognosis**
- ❖ **Assessment of treatment response**


Factors affecting biliary cholesterol saturation

5F rule

- ❖ Age: decline of cholesterol 7α hydroxylase activity – CYP7A1 (FORTY)

Klasická (neutrální) biosyntetická dráha

Alternativní (kyselá) biosyntetická dráha





Factors affecting biliary cholesterol saturation

5F rule

- ❖ **Age: decline of cholesterol 7a hydroxylase activity – CYP7A1 (FORTY)**
- ❖ **Sex: CSI higher by 15 - 20% in women (FEMALE)**
- ❖ **Hormonal influences: estrogens increase biliary cholesterol secretion (FERTILE)**
- ❖ **Obesity, rapid weight loss (FATTY)**
- ❖ **White population (FAIR)**
- ❖ **Diet and drugs (fiber, fibrates, statins...)**



Bilirubin

- ❖ Thanks to its conformation, unconjugated bilirubin is non-polar and reacts in diazo reaction "indirectly",
- ❖ whereas conjugated bilirubin is polar and reacts "directly"




❖ Division of hyperbilirubinemias on:

- ❖ Premicrosomal
- ❖ Postmicrosomal
- ❖ Mixed




Bilirubin metabolism in the liver cell




Delta bilirubin


- ❖ Is formed by transesterification of glucuronosyl bilirubin in long-term conjugated hyperbilirubinemias
- ❖ Is not secreted to urine
- ❖ Reacts "directly" with diazo reagent
- ❖ Albumin half-life determines half-life of delta-bilirubinemia




Principle of bilirubin diazo-reaction




bisglukuronosyl bilirubin



*diazotovaná
kyselina sulfanilová*



azobilirubin (izomer I)



azobilirubin (izomer II)

Can UDCA be administered in breast-feeding mothers?

“It is not known, whether UDCA is transported to breast milk, it is thus not recommended to administer drug during breast-feeding.”

SPC Ursofalk® 8.9. 2004

“It is not known, whether UDCA is transported to breast milk. Plasma levels in mothers are minimal. UDCA administration during breast-feeding, especial risks and potential benefits must be assessed by a medical doctor.

SPC Ursosan® 1.1. 2007

Hepatocellular damage markers I

- ❖ **AST – low specificity**

- ❖ **liver**

- ❖ **myocardium**

- ❖ **skeletal muscles**

- ❖ **kidney**

- ❖ **pancreas**

- ❖ **erythrocytes**

- ❖ **mitochondrial (70%) a cytoplasmatic (30%)
isoenzyme**

Hepatocellular damage markers II

❖ ALT

- ❖ relative specificity
- ❖ in cytosol of hepatocytes
- ❖ Elevation of ALT and cytoplasmic isoenzyme of AST – increased membrane permeability (1 damaged hepatocyte out of 2000)
- ❖ Elevation of mitochondrial AST – hepatocellular necrosis.
- ❖ Ratio AST/ALT (de Ritis index) – values above 1: worse prognosis

Hepatocellular damage markers III

- ❖ **Extreme values of aminotransferases (more than 20x)**
- ❖ **Acute toxic damage of the liver**
- ❖ **Fulminant hepatitis**
- ❖ **Liver hypoperfusion (shock, acute heart failure)**

Cholestatic markers I

- ❖ **S-alkaline phosphatase (ALP)**
 - ❖ **Several isoenzymes, mainly bone, hepatic, intestinal and placental**
 - ❖ **Intestinal isoenzyme- elevation when hepatic uptake is decreased. Only in subjects with ABO blood group 0 and B (Intestinal ALP is bound to RBC of blood group A)**
 - ❖ **Odysseus syndrome**
 - ❖ **Electrofoculation: 19 isoenzymes (Griffith)**
 - ❖ **Liver: 7 different forms, „biochemical biopsy of the liver“**
 - ❖ **macro ALP**

Cholestatic markers II

- ❖ **S-gammaglutamyltransferase (GGT)**
 - ❖ In tissues with excretory or absorption function
 - ❖ Also in prostate (increase by 50% in men) and in placenta (higher c in newborns)
 - ❖ Liver: in microsomal fraction and in cell membranes of bile duct lining
 - ❖ Sensitive, but non-specific marker of liver diseases
- ❖ **S- Bile acids**

Synthetic function markers I

- ❖ **S-albumin**
 - ❖ **Half-life 18-21 days**
 - ❖ **hypoalbuminaemia:**
 - ❖ **Decreased synthesis**
 - ❖ **Sequestration in EV space (ascites)**
 - ❖ **Increased catabolism in fever or trauma**
 - ❖ **Decreased intake of protein**
 - ❖ **Malabsorption**
 - ❖ **Loss in kidney disease, burns or protein-losing enteropathy**

Synthetic function markers II

- ❖ **S-prealbumin**
 - ❖ **Half-life 1,9 days**
- ❖ **S-cholinesterase (CHE)**
 - ❖ **Activity in many organs, several isoenzymes**
 - ❖ **total CHE- predominantly of hepatic origin**
 - ❖ **Decrease also in organophosphate poisoning**
 - ❖ **Increase in Gilbert syndrome and alcohol abuse**
- ❖ **S-coagulation factors, routinely PT, protein C and f VII: the shortest half-life**